Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Hyunji, Jo"'
Autor:
Soo-Yeon Hwang, Kyung-Hwa Jeon, Hwa-Jong Lee, Inhye Moon, Sehyun Jung, Seul-Ah Kim, Hyunji Jo, Seojeong Park, Misun Ahn, Soo-Yeon Kwak, Younghwa Na, Youngjoo Kwon
Publikováno v:
eLife, Vol 13 (2024)
HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success; ho
Externí odkaz:
https://doaj.org/article/299cfce3e3f844a5afe06b7ebbe171b3
Publikováno v:
Biosensors, Vol 14, Iss 11, p 539 (2024)
Glioblastoma multiforme (GBM) is among the most aggressive brain cancers, and it contains glioma stem cells (GSCs) that drive tumor initiation, progression, and recurrence. These cells resist conventional therapies, contributing to high recurrence ra
Externí odkaz:
https://doaj.org/article/3a50c3738f2c46509e85b425143d84bc
Autor:
Soo-Yeon Hwang, Seojeong Park, Hyunji Jo, Seung Hee Seo, Kyung-Hwa Jeon, Seojeong Kim, Ah-Reum Jung, Chanju Song, Misun Ahn, Soo Yeon Kwak, Hwa-Jong Lee, Motonari Uesugi, Younghwa Na, Youngjoo Kwon
Publikováno v:
Journal of Advanced Research, Vol 47, Iss , Pp 173-187 (2023)
Introduction: HER2 overexpression induces cancer aggression and frequent recurrences in many solid tumors. Because HER2 overproduction is generally followed by gene amplification, inhibition of protein–protein interaction (PPI) between transcriptio
Externí odkaz:
https://doaj.org/article/c514c7b5d10c489d80d09349a306cdd7
Autor:
Hongsik Kim, Ryul Kim, Hyunji Jo, Hye Ryeon Kim, Joohyun Hong, Sang Yun Ha, Joon Oh Park, Seung Tae Kim
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Background: Expression of programmed death-ligand 1 (PD-L1) has been reported to correlate with response to immune checkpoint inhibitors (ICIs) in various tumor types. However, there are few data on the role of PD-L1 expression as a predictive and pr
Externí odkaz:
https://doaj.org/article/919143fb97924cfb80ed8df532815d79
Autor:
Hyunji Jo, Joohyun Hong, Hongsik Kim, Hye Ryeon Kim, Ghee Young Kwon, Kyung A. Kang, Sung Yoon Park, Chan Kyo Kim, Byung Kwan Park, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Se Hoon Park
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
PurposePatients with International Metastatic RCC Database Consortium (IMDC) poor risk metastatic renal cell carcinoma (mRCC) rarely respond to first-line tyrosine kinase inhibitors (TKIs) including sunitinib, and carries a very poor prognosis. In re
Externí odkaz:
https://doaj.org/article/d54aa331e55345cfab3849aa5aec1ee0
Autor:
Hongsik Kim, Ryul Kim, Hye Ryeon Kim, Hyunji Jo, Hana Kim, Sang Yun Ha, Joon Oh Park, Young Suk Park, Seung Tae Kim
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
HER2 aberrations have been reported as a novel biomarker in HER2-directed therapy or as a prognostic marker in various tumor types. However, in advanced biliary tract cancer (BTC), there have been few studies regarding HER2 aberrations as a biomarker
Externí odkaz:
https://doaj.org/article/5e4b89c2f10e47c5b4f8a0fe7c49f9d7
Autor:
Hyunji Jo1, Seung Tae Kim1, Jeeyun Lee1, Se Hoon Park1, Joon Oh Park1, Young Suk Park1, Ho Yeong Lim1, Jeong Il Yu2, Hee Chul Park2, Doo Ho Choi2, Yoonah Park3, Yong Beom Cho3, Jung Wook Huh3, Seong Hyeon Yun3, Hee Cheol Kim3, Woo Yong Lee3, Won Ki Kang1
Publikováno v:
Cancer Research & Treatment. Jan2023, Vol. 55 Issue 1, p189-195. 7p.
Autor:
Hye Ryeon Kim1,2, Hyunji Jo1, Hongsik Kim1, Joohyun Hong1, Sehhoon Park1, Hyun Ae Jung1, Se-Hoon Lee1, Jin-Seok Ahn1, Myung-Ju Ahn1
Publikováno v:
Cancer Research & Treatment. Jan2023, Vol. 55 Issue 1, p344-349. 6p.
Autor:
Hye Ryeon Kim, Soomin Ahn, Hyunji Jo, Hongsik Kim, Joohyun Hong, Jeeyun Lee, Ho-Yeong Lim, Won Ki Kang, Seung Tae Kim
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundTrastuzumab is a HER2-trargeted humanized monoclonal antibody that has been studied as a first-line treatment for patients with HER2-positive advanced gastric cancer (AGC). The effect of anti-HER2 therapy according to tumor mutational burde
Externí odkaz:
https://doaj.org/article/3aabafd8b49749279f87e8b796907259
Autor:
Hongsik Kim MD, Hana Kim MD, Ryul Kim MD, PhD, Hyunji Jo MD, Hye Ryeon Kim MD, Joohyun Hong MD, PhD, Joon Oh Park MD, PhD, Young Suk Park MD, PhD, Seung Tae Kim MD, PhD
Publikováno v:
Technology in Cancer Research & Treatment, Vol 20 (2021)
Background : High tumor mutational burden (TMB-H) has been reported as a predictive marker to immunotherapy or prognostic marker in various tumor types. However, there has been little study of the role of TMB-H in advanced biliary tract cancer (BTC).
Externí odkaz:
https://doaj.org/article/83fd42d3d7f54068817202539c732b95